Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2026 | $10.00 | Mkt Outperform | Citizens |
| 7/2/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 3/7/2024 | $12.00 | Buy | Lake Street |
| 10/27/2023 | $12.00 | Buy | Craig Hallum |
| 10/13/2022 | $7.00 | Buy | Mizuho |
| 9/14/2021 | $20.00 → $8.50 | Buy | HC Wainwright & Co. |
| 7/26/2021 | $23.00 | Outperform | Northland Capital |
Citizens initiated coverage of MiMedx Group with a rating of Mkt Outperform and set a new price target of $10.00
Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00
Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00
MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Ricci joined the Company at a pivotal time in the organizatio
Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care ("SAWC") Spring 2026 and MedStar Georgetown University Hospital's Diabetic Limb Salvage ("DLS") Conference. Through scientific presentations, clinician education, and exhibit presence, MIMEDX will highlight its growing body of clinical evidence and expanding portfolio of solutions designed to support clinicians in m
MARIETTA, Ga., March 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of CHORIOFIX™, the latest advanced wound care innovation in its product portfolio of placental allografts. "CHORIOFIX is an organically developed product, created based on our deep understanding of the scientific and clinical attributes of the chorion layer," stated Michelle Massee, MIMEDX VP, Research & Development. "It consists of two chorion layers with an intact intermediate layer, making it our thickest product to date. The allograft's structure enhances handling, particularly during positioning and suturing, while its uniform, dual-side
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
10-K - MIMEDX GROUP, INC. (0001376339) (Filer)
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe
MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a
MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Ricci joined the Company at a pivotal time in the organizatio
Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2025. Joseph H. Capper, MIMEDX Chief Executive
MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13758446 A replay of the webcast will be available for approximately 30 days on
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)